Could a Novel Oral Therapy Change How Clinicians Treat OSA?

Name: Could a Novel Oral Therapy Change How Clinicians Treat Obstructive Sleep Apnea? Insights From the SynAIRgy Trial
Uploaded: 2026-09-04T04:00:00+00:00
Description: In this episode, Patrick J. Strollo Jr, MD, FACP, FCCP, FAASM, of the University of Pittsburgh Department of Medicine, Pittsburgh, PA, discusses the data f

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Functional Neurologic Symptom Disorder Resolving After Endoscopic Encephalocele Repair
Functional Neurologic Symptom Disorder Resolving After Endoscopic Encephalocele Repair
Epilepsy & Seizures
Functional Neurologic Symptom Disorder Resolving After Endoscopic Encephalocele Repair
Charles F. Palmer, MD; Rodney J. Schlosser, MD
Charles F. Palmer, MD; Rodney J. Schlosser, MD
Movement Disorders Moment: Sleep-Related Movement Disorders—A Review
Movement Disorders Moment: Sleep-Related Movement Disorders—A Review
Movement Disorders
Movement Disorders Moment: Sleep-Related Movement Disorders—A Review
Morris Chang, MD
Morris Chang, MD
Bridging the Gap: How Online Patient Discussions Can Transform Narcolepsy Care
Bridging the Gap: How Online Patient Discussions Can Transform Narcolepsy Care
Sleep
Bridging the Gap: How Online Patient Discussions Can Transform Narcolepsy Care
Jennifer Gudeman, PharmD, Senior Vice President, Medical and Clinical Affairs of Avadel Pharmaceuticals plc
Jennifer Gudeman, PharmD, Senior Vice President, Medical and Clinical Affairs of Avadel Pharmaceuticals plc
The Potential of Orexin Science: Searching for a Novel Approach to Treat Narcolepsy Type 1
The Potential of Orexin Science: Searching for a Novel Approach to Treat Narcolepsy Type 1
Sleep
The Potential of Orexin Science: Searching for a Novel Approach to Treat Narcolepsy Type 1
Alice Cai, MD, Medical Director, Takeda Pharmaceuticals
Alice Cai, MD, Medical Director, Takeda Pharmaceuticals